Antibody Reveals Conformational Latch Controlling Herpesvirus Proteases
Preprint
Abstract
Human herpesviruses (HHVs) are widespread pathogens that cause severe disease. Their replication depends on the HHV protease (HHV Pr), an enzyme essential for capsid maturation. Because HHV Pr must dimerize to become catalytically active, disrupting dimer formation is a promising strategy for antiviral therapeutic development. We isolated a conformationally selective antibody inhibitor, Fab5, from a fully human naïve Fab-phage library that recognizes monomeric human cytomegalovirus protease (HCMV Pr). A 2.6 Å cryoelectron microscopy (cryo-EM) structure of the Fab5-HCMV Pr complex revealed that Fab5 binds a flexible loop distal from the active site and dimer interface which we call the latch loop. In HCMV Pr dimers, this loop secures the C-terminal tail to the protein core. Structure-guided mutagenesis confirmed that the latch loop is essential for HCMV Pr dimerization and activity. This loop is structurally conserved across all HHV Prs, and we show its functional role in Kaposi’s Sarcoma-associated herpesvirus (KSHV) Pr as well. The latch loop plays a mechanistic role in the conformational transition required for HHV Pr activity, and it forms a cryptic site that presents a new avenue for future allosteric inhibitor development.Keywords
Funding Information
- NIH (U54AI170792)
- NIH (R35GM140847)
- NIH (S10OD020054)
- NIH (S10OD021741)
- NIH (S10OD026881)
This publication has 40 references indexed in Scilit:
- Dynamic allostery drives autocrine and paracrine TGF-β signalingCell, 2024
- Selective Intracellular Delivery of Antibodies in Cancer Cells with Nanocarriers Sensing Endo/Lysosomal Enzymatic ActivityAngewandte Chemie International Edition, 2024
- Inhibiting a dynamic viral protease by targeting a non-catalytic cysteineCell Chemical Biology, 2022
- The effect of dimerization and ligand binding on the dynamics of Kaposi's sarcoma‐associated herpesvirus proteaseProteins: Structure, Function, and Bioinformatics, 2022
- Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificityBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2021
- Why recombinant antibodies — benefits and applicationsCurrent Opinion in Biotechnology, 2019
- Pharmaceutical Development of AAV-Based Gene Therapy Products for the EyePharmaceutical Research, 2018
- Antiviral Therapies for Herpesviruses: Current Agents and New DirectionsClinical Therapeutics, 2018
- Structure of an Fab–Protease Complex Reveals a Highly Specific Non-canonical Mechanism of InhibitionJournal of Molecular Biology, 2008
- The kinetics of enzyme-catalyzed reactions with two or more substrates or productsBiochimica et Biophysica Acta (BBA) - Specialized Section on Enzymological Subjects, 1963